Abstract: Encapsulated nucleic acid nanoparticles of uniformly small particle size are produced by intersecting one or more nucleic acid streams with one or more lipid streams. The encapsulated nucleic acid nanoparticles include a nucleic acid encapsulated within a lipid nanoparticle host. Uniformly small particle sizes are obtained by intersecting an aqueous nucleic acid stream and a stream of lipids in organic solvent at high linear velocities and with total organic solvent concentrations less than 33%.
Type:
Application
Filed:
July 10, 2015
Publication date:
July 13, 2017
Inventors:
Keith A. BOWMAN, Noah GARDNER, Travis JEANNOTTE, Chandra VARGEESE
Abstract: Processes and apparatuses for producing biologically-active, protein-rich microparticles under ambient conditions are disclosed. A protein solution is atomized and collected in a dehydration solvent that is being mixed. The resulting protein microparticles retain high specific activity without the need for large amounts of stabilizing excipients.
Type:
Application
Filed:
March 28, 2017
Publication date:
July 13, 2017
Inventors:
Trevor Petrel, Craig Bartling, Lena Furci, Carrie Howland
Abstract: A core-shell particle formulation for delivering multiple therapeutic agents is disclosed. More particularly, core-shell particle formulation configured to independently release therapeutic agents from the core and the shell. Moreover, the core-shell particle bearing therapeutic agents enables treatment against the diseases such as cancer, inflammatory and auto-immune diseases.
Abstract: Biochars and methods for treating biochars are provided that are useful in various applications, including, but not limited to, applications related to the raising, care, maintenance, disease prevention, disease treatment and odor control of animals.
Type:
Application
Filed:
January 30, 2017
Publication date:
July 13, 2017
Inventors:
Richard Wilson Belcher, Ranko Panayotov Bontchev, Han Suk Kim, Gregory Dean Butler, Brian Buege, Juliette MacKay
Abstract: Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product.
Abstract: Sustained-released beads providing active ingredients over an extended period of time to an individual orally ingesting the sustained release beads. The sustained-release beads can be part of a suspension wherein the sustained-release beads are suspended and evenly dispersed in the suspension. Binding agents are used to form the structural framework of the sustained released beads and retain the active ingredients without chemical or electrical bonding. The components of the dispersion medium are GRAS designated, making the suspension suitable for use as a food product.
Abstract: The invention provides a particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%. The invention also provides a process for preparation of the hollow particle, which includes a step of granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer.
Abstract: A laser-printable tablet has: a tablet containing an optically unstable drug, a first cover layer that covers the tablet and contains a first color change-inducing oxide, and a second cover layer that covers the first cover layer and contains a second color change-inducing oxide, the concentration in which the second color change-inducing oxide is contained in the second cover layer being different from the concentration in which the first color change-inducing oxide is contained in the first cover layer.
Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release.
Abstract: The present invention provides injectable compositions comprising cells encapsulated in hydrogel capsules and methods of preparing these compositions. The present invention also provides methods for using these compositions to promote hematopoiesis and to treat or prevent cardiovascular and immunological disorders in a subject.
Type:
Application
Filed:
June 30, 2015
Publication date:
July 13, 2017
Inventors:
Jae-Won Shin, Angelo S. Mao, Stefanie Utech, David A. Weitz, David J. Mooney, Oktay Uzun
Abstract: Embodiments of the claimed invention are directed to a biodegradable mucosal bioadhesive composition that delivers a therapeutic agent specifically to the target site, without loss to saliva or absorption by non-targeted areas. In certain embodiments, the outer layer of the composition also protects the covered area from physical contact.
Abstract: The present invention provides a method of using (E)-1-(3?, 4?-dimethoxyphenyl) butadiene to induce anti-tumorigenic effects in pancreatic carcinoma, ovarian carcinoma and prostate carcinoma. The invention also provides a method of using (E)-1-(3?, 4?-dimethoxyphenyl) butadiene to prevent cancer metastasis.
Type:
Application
Filed:
November 24, 2016
Publication date:
July 13, 2017
Inventors:
Muhammed Majeed, Kalyanam Nagabhushanam
Abstract: A method of inhibiting mucus secretion in an individual that includes administering an effective amount of a composition which comprises guaifenesin.
Type:
Application
Filed:
March 28, 2017
Publication date:
July 13, 2017
Inventors:
Helmut Albrecht, K. Chul Kim, Bruce Rubin, Jeanclare Seagrave, Gail Solomon
Abstract: The use of tapentadol (i) in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) in the treatment or the inhibition of depression or anxiety.
Type:
Application
Filed:
March 27, 2017
Publication date:
July 13, 2017
Inventors:
Ilona STEIGERWALD, Ulrich JAHNEL, Thomas TZSCHENTKE
Abstract: The present invention provides a composition comprising HMB. Methods of administering HMB to an animal are also described. HMB is administered to decrease joint instability, increase joint stability, decrease joint stiffness, improve joint function, improve joint health, improve balanced movement and improve skeletal joint stability during muscle movement. HMB is administered to increase muscle strength and/or muscle mass in a side of the body contralateral to joint inflammation, joint damage, and/or joint injury.
Type:
Application
Filed:
January 13, 2017
Publication date:
July 13, 2017
Inventors:
John Fuller, JR., John Rathmacher, Emily Harris, Shawn Baier
Abstract: The present disclosure provides orally deliverable pharmaceutical compositions comprising DGLA and methods of using same to treat a variety of conditions and disorders.
Type:
Application
Filed:
January 6, 2017
Publication date:
July 13, 2017
Inventors:
Mehar Manku, John Climax, David Coughlan, James Dunne
Abstract: The present invention relates to medicaments based on oligomeric forms of 3-hydroxybutyrate, particularly 3-hydroxybutyrate methyl ester dimer (1) and trimer (2), especially for use in treating, preventing and/or inhibiting development of a disorder or condition related to oxidative stress. The present invention relates also to the use of these molecules as antioxidants, and to a method for increasing proliferation and viability of plant cells in the aid of molecules 1 and 2.
Type:
Application
Filed:
July 21, 2015
Publication date:
July 13, 2017
Inventors:
Anna Maria Pirttilä, Janne Koshiimäki, Sampo Mattila, Marena Kajula, Juho Hokkanen, Bruce Campbell
Abstract: Described herein is the surprising discovery that ketone bodies protect cell and tissues from ionizing radiation. Based on this finding, methods of protecting animal tissue and cells from damage caused by radiation exposure are disclosed which include, contacting the tissue with a therapeutically effective amount of an agent including at least one ketone ester, thereby protecting the tissue from radiation damage. Ketone esters can be used to minimize, reduce and/or prevent tissue damage following intentional and accidental radiation exposure, as well as increasing the therapeutic efficacy of radiation therapies by protecting non-target tissue from incidental radiation damage.
Abstract: Disclosed herein are for example, liquid aqueous compositions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome, dystonia, and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of levodopa and/or carbidopa or ester and/or salt thereof.
Abstract: The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enhancing the cognitive function of a patient in need thereof. Such methods may include administering a therapeutically effective amount of a MetAP2 inhibitor.
Abstract: The present disclosure relates to modified or polymer conjugated MetAP2 inhibitors. The present disclosure also relates to methods of treating metabolically-driven diseases and disorders, such as certain cancers.
Abstract: Described are nanoparticle complexes comprising paclitaxel, albumin and anti-HER2 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses HER2.
Type:
Application
Filed:
January 23, 2017
Publication date:
July 13, 2017
Applicant:
Mayo Foundation for Medical Education and Research
Abstract: Described are nanoparticle complexes comprising paclitaxel, albumin and anti-CD52 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses CD52.
Type:
Application
Filed:
January 23, 2017
Publication date:
July 13, 2017
Applicant:
Mayo Foundation for Medical Education and Research
Abstract: Described are nanoparticle complexes comprising paclitaxel, albumin and anti-HER2 antibody. The nanoparticle complexes are suitable for the treatment of cancer, in particular cancer that expresses VEGF.
Type:
Application
Filed:
January 23, 2017
Publication date:
July 13, 2017
Applicant:
Mayo Foundation for Medical Education and Research
Abstract: The present invention discloses a preparation and application of flavonol as a brain-targeting synergist. After long-term repeated studies, the inventors have found that some flavonol compounds, particularly kaempferide, rutin, troxerutin, myricetin, hesperidin, and hydroxy derivatives thereof, in particular their glycoside, ester, ether derivatives, can promote the drug molecules that have therapeutic or healthcare effect, such as ginsenoside, stilbene glucoside, resveratrol, levodopa, edaravone, vinpocetine, nicergoline, citicoline, oxiracetam, to enter brain tissues, to dramatically enhance drugs concentrations in the brain tissues and effective enhance the efficacy of drugs without increasing the plasma concentration.
Abstract: The present disclosure provide a combination of a chromene compound having the structure of Formula (I), or pharmaceutically acceptable salts, and a second compound that can be selected from a PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, OX-40 agonist, CD137 agonist, LAG-3 inhibitor, IDO inhibitor, bi-specific protein, EGFR inhibitor, HER2 inhibitor, and immune stimulating therapy and a method of using the combination for treating or preventing cancer.
Type:
Application
Filed:
January 9, 2017
Publication date:
July 13, 2017
Inventors:
John J. TALLEY, Bobby W. SANDAGE, JR., Eduardo J. MARTINEZ
Abstract: The present invention includes compositions and methods for the treatment of cancer comprising an antineoplastic drug and an inhibitor of chromosome maintenance region 1 (CRM1) protein expression or activity, wherein the inhibitor of CRM1 enhances the anti-neoplastic effect of the antineoplastic drug.
Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.
Type:
Application
Filed:
December 20, 2016
Publication date:
July 13, 2017
Inventors:
Sreedhara ALAVATTAM, Mary MALLANEY, Parbir GREWAL
Abstract: The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection.
Type:
Application
Filed:
September 28, 2016
Publication date:
July 13, 2017
Inventors:
Gregory A. Demopulos, Hui-rong Shen, Clark E. Tedford
Abstract: The invention relates to methods for neuroprotection, promoting survival of motor neurons and the treatment of motor neuron diseases by preventing cell signaling through the classic prostaglandin D2 receptor DP1.
Type:
Application
Filed:
November 9, 2015
Publication date:
July 13, 2017
Inventors:
Kevin C. Eggan, Francesco Paolo Di Giorgio
Abstract: Described herein are modified androgen receptor polypeptides that are resistant to inhibition by an androgen receptor inhibitor. Described herein are compositions, combinations, and kits containing the modified androgen receptor polypeptides and methods of using the modified androgen receptor polypeptides. Also described herein are methods of using the modified androgen receptor polypeptides as screening agents for the identification and design of third-generation androgen receptor modulators. Also described herein are third-generation androgen receptor modulators that inhibit the activity of the modified androgen receptor polypeptides. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions, including cancers, such as castration resistant prostate cancers, that are mediated or dependent upon androgen receptors.
Type:
Application
Filed:
March 1, 2017
Publication date:
July 13, 2017
Inventors:
JAMES DAVID JOSEPH, JEFFREY H. HAGER, JOHN LEE SENSINTAFFAR, NHIN LU, JING QIAN, NICHOLAS D. SMITH
Abstract: In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
Type:
Application
Filed:
November 21, 2016
Publication date:
July 13, 2017
Applicant:
THERAVANCE BIOPHARMA R&D IP, LLC
Inventors:
Melissa Fleury, Adam D. Hughes, Anne-Marie Beausoleil, Erik Fenster, Venkat R. Thalladi, Miroslav Rapta
Abstract: Provided herein are methods of treating, preventing, ameliorating or managing mucopolysaccharidosis (nmMPS) disease, comprising administering a 1,2,4-oxadiazole benzoic acid to a patient having a nmMPS. In particular, provided herein are methods of treating, preventing, ameliorating or managing a MPS.
Abstract: The present disclosure relates to pharmaceutical compositions useful for (and to a method of) treating autoimmune, respiratory and/or inflammatory diseases and conditions. The method involves administering to a subject in need thereof roflumilast N-oxide by inhalation. The present disclosure particularly relates to the treatment of asthma and chronic obstructive pulmonary disease (COPD) by administering roflumilast N-oxide by inhalation.
Abstract: The present invention relates to compounds of Formula (I): wherein X1, X2, X3, X4, X5, X6, X7, X8, R1, R2, R3 are as defined above. The compounds have apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and are thus useful in the treatment of ASK1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases. The invention also relates to pharmaceutical compositions comprising one or more of the compounds of Formula (I), and to methods of preparing the compounds of Formula (I).
Type:
Application
Filed:
January 23, 2017
Publication date:
July 13, 2017
Inventors:
MICHAEL GRAUPE, Keith Koch, Britton Kenneth Corkey, Gregory Notte, Lawrence S. Melvin, JR.
Abstract: Methods for preventing, treating, and/or reducing the risk of developing non-alcoholic fatty liver disease in a subject in need thereof and pharmaceutical compositions for the prevention or treatment of non-alcoholic fatty liver disease. Methods for inhibiting excessive accumulation of fat in liver tissue. The methods include administering to the subject or contacting the liver tissue with a therapeutically effective amount of at least one compound of General Formula (I) or General Formula (II): or pharmaceutically-acceptable salts or solvates thereof. The pharmaceutical composition includes at least one compound of the General Formula (I) or the General Formula (II) for administration to a subject for the prevention or treatment of non-alcoholic fatty liver disease.
Type:
Application
Filed:
May 6, 2015
Publication date:
July 13, 2017
Applicant:
Ohio University
Inventors:
Kelly D. McCall, Frank L. Schwartz, Douglas J. Goetz
Abstract: The invention relates to methods of treating attention deficit hyperactivity disorder in patients in need thereof, and methods for selecting therapeutic dosage amounts to achieve the desired efficacy more quickly. More specifically, the methods of the present invention provide for methylphenidate treatment regimens wherein the efficacious dosage amounts are selected based upon the body weight of the patient to be treated.
Abstract: Provided herein are lyophilized formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. Methods of using the formulations and dosage forms for treating, managing, and/or preventing cancer are also provided herein.
Abstract: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
Type:
Application
Filed:
January 23, 2017
Publication date:
July 13, 2017
Inventors:
Laura Cook Blumberg, Julius F. Remenar, Orn Almarsson, Tarek A. Zeidan
Abstract: Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
Type:
Application
Filed:
March 27, 2017
Publication date:
July 13, 2017
Inventors:
Asa Rosenquist, Fredrik Thorstensson, Per-Ola Johansson, Ingemar Kvarnstrom, Bertil Samuelsson, Hans Wallberg
Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
Type:
Application
Filed:
January 25, 2017
Publication date:
July 13, 2017
Inventors:
Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
Abstract: The invention describes pharmaceutical compounds and compositions comprised of a ligand attached to opioids in a manner that substantially decreases or deters the potential for opioid abuse, addiction, illicit and illegal use, and overdose. When delivered at the proper dosage, the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.
Abstract: The presently disclosed subject matter provides a pharmaceutical composition and a method of treating Chagas disease. The pharmaceutical composition includes a dose of Itraconazole and a dose of Amiodarone and may be in the form of a liquid oral suspension. The liquid oral suspension may be produced through the use of pharmaceutically acceptable beads. In addition, the Itraconazole may be micronized to a small particle size before being formed into a composition with Amiodarone. The method for treating Chagas disease is effected by administering an effective amount of this pharmaceutical composition to a subject in need thereof, and the present composition is safer and more effective than previous compositions and with fewer undesirable side effects.
Abstract: A treatment of patients afflicted with prostate cancer, wherein the treatment includes administering to a mammal in need thereof at least one tyrosine kinase inhibitor or mast cell inhibitor that is an inhibitor of kinase activity selected from the tyrosine kinases of: c-Kit, PDGFR, LYN, FYN, or any combination thereof, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient.
Type:
Application
Filed:
June 2, 2014
Publication date:
July 13, 2017
Inventors:
Alain MOUSSY, Jean-Pierre KINET, Colin MANSFIELD
Abstract: This invention is directed to compounds and salts that are generally useful as agents to treat an infection with Dirofilaria immitis. This invention also is directed to treatments comprising the administration of the compounds and salts to animals in need of the treatments.
Type:
Application
Filed:
July 10, 2015
Publication date:
July 13, 2017
Applicant:
Intervet Inc.
Inventors:
Christophe Pierre Alain Chassaing, Jurgen Lutz, Anja Regina Heckeroth
Abstract: The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C6-C24 fatty acid, or (b) a hydrophilic organic compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and dimethylsulfoxide, or (c) a combination of (a) and (b), and (iii) an amphiphilic agent wherein the active pharmaceutical ingredient is dispersed as discrete particles having a D90 particle size of about 0.5 ?m to about 25 ?m in the formulation, and wherein the formulation is non-gelling and thixotropic with a viscosity of less than 10 poise at a shear rate of 10/s at 25° C.
Type:
Application
Filed:
October 24, 2016
Publication date:
July 13, 2017
Applicant:
Abon Pharmaceuticals, LLC
Inventors:
Salah U. AHMED, Yanming ZU, Jason LePREE, Hetalben PRAJAPATI, Tahseen A. CHOWDHURY
Abstract: The present invention relates to a pharmaceutical composition comprising sorbitan esters of carboxylic acids that are useful for the delivery of anti-psychotic drugs.
Type:
Application
Filed:
December 22, 2016
Publication date:
July 13, 2017
Inventors:
Jason M. Perry, Daniel R. Deaver, Magali B. Hickey, Julius F. Remenar, Jennifer Vandiver
Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
Type:
Application
Filed:
March 10, 2017
Publication date:
July 13, 2017
Inventors:
Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Allyson K. Palmer
Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
Type:
Application
Filed:
March 10, 2017
Publication date:
July 13, 2017
Inventors:
Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, Darren J. Baker, Bennett G. Childs, James L. Kirkland, Tamar Tchkonia, Jan M.A. van Deursen, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Allyson K. Palmer